Apollomics Stock Set to Reverse Split on Monday, November 25th (NASDAQ:APLM)

Apollomics, Inc. (NASDAQ:APLM) shares are scheduled to reverse split before the market opens on Monday, November 25th. The 1-100 reverse split was announced on Thursday, November 21st. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, November 22nd.

Apollomics Stock Performance

Shares of Apollomics stock traded down $0.05 during midday trading on Thursday, hitting $0.10. The company had a trading volume of 11,199,390 shares, compared to its average volume of 9,109,365. The company has a 50 day moving average of $0.13 and a 200 day moving average of $0.18. Apollomics has a 52-week low of $0.08 and a 52-week high of $1.23.

Hedge Funds Weigh In On Apollomics

An institutional investor recently raised its position in Apollomics stock. George Kaiser Family Foundation lifted its stake in Apollomics, Inc. (NASDAQ:APLM) by 2,585.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 670,976 shares of the company’s stock after purchasing an additional 645,992 shares during the period. Apollomics accounts for approximately 0.0% of George Kaiser Family Foundation’s holdings, making the stock its 18th largest position. George Kaiser Family Foundation owned about 0.75% of Apollomics worth $141,000 as of its most recent SEC filing. Institutional investors and hedge funds own 19.13% of the company’s stock.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.